This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Astex Pharmaceuticals Announces Initiation Of SGI-110 Phase 2 Trial In Platinum-Resistant Recurrent Ovarian Cancer Patients

DUBLIN, Calif., Oct. 2, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, announced that it has initiated a Phase 2, open label, randomized, multi-center, controlled clinical trial, evaluating SGI-110 in combination with carboplatin in platinum-resistant recurrent ovarian cancer patients.

Study SGI-110-02 will have two stages: a safety lead-in stage (Stage A) followed by a randomized, controlled, open-label stage (Stage B). In Stage A of the study, patients will receive escalating doses of SGI-110 and carboplatin to define the Maximum Tolerated Dose (MTD) and preliminary biological and clinical activity. Once the MTD is defined, and biological activity confirmed, the study will proceed to Stage B. In Stage B of the study, patients will be randomized to receive SGI-110 plus carboplatin at the MTD identified in Stage A, or one of three treatment of choice, standard of care agents, as determined by the clinical investigator: topotecan, pegylated liposomal doxorubicin, or paclitaxel. The primary endpoint in Stage B will be a comparison of progression free survival (PFS) between SGI-110 plus carboplatin, and treatment of choice study arms. Response rate and overall survival will be among the secondary endpoints.

Stage A will enroll approximately 20 patients, and Stage B will enroll 96 patients.   

The study is based on preclinical work showing that SGI-110  reverses platinum resistance, and on a clinical study with Dacogen® and carboplatin showing a 35% response rate and 10.2 months median PFS in heavily pretreated platinum-resistant ovarian cancer patients (Matei et al, Cancer Res 2012; 72:2197–2205).

"There is a great need for agents to reverse platinum-resistance as platinum is still the most active agent in ovarian cancer and other tumor types. This proof of concept study will establish the role of SGI-110 in reversing the epigenetic based resistance in patients receiving platinum based standard of care treatment," said Mohammad Azab, MD, chief medical officer. "We are pleased to commence investigational studies of SGI-110 in ovarian cancer with this first ever randomized clinical trial of a DNA hypomethylating agent in combination with platinum in platinum-resistant patients."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,630.27 +189.68 1.09%
S&P 500 2,093.25 +25.61 1.24%
NASDAQ 5,089.2060 +49.43 0.98%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs